In short: A Biofibre hair transplant is synthetic fibre implantation, not transplantation of your own living follicles. The current ISHRS position aligns with the US FDA ban on the prosthetic-hair-fibre category, while a 2025 Biofibre case report records one delayed inflammatory reaction and cannot show how often this happens.

A Biofibre hair transplant places manufactured fibres in the scalp. It does not move your own living hair follicles, so the word "transplant" can give the wrong impression about what the procedure involves (ISHRS; NHS).

The International Society of Hair Restoration Surgery (ISHRS) aligns with the US Food and Drug Administration’s position on prosthetic hair fibres. A 2025 report describes a foreign-body reaction after Biofibre implantation, but one case cannot estimate the frequency of that problem (ISHRS; 2025 case report).

What is a Biofibre hair transplant?

Biofibre is a brand name used in the published 2025 case report for synthetic filaments implanted into the scalp. The report describes the material as exogenous, meaning that it came from outside the body, and identifies the procedure as synthetic hair implantation (2025 case report).

The ISHRS treats "prosthetic hair fibres", "artificial hair fibres" and "synthetic hair fibres" as names for the same category (ISHRS). They are separate from externally attached hair systems, and they are also separate from surgery that relocates a person’s own hair-bearing tissue or follicles.

Calling the procedure a hair transplant does not turn the fibres into living grafts (21 CFR 895.101; NHS). Evidence about conventional follicular transplantation cannot be transferred to an implanted-fibre procedure without support. Regulation and complication data also need to match the exact procedure.

The reviewed sources provide no current regulatory documentation showing whether Biofibre is approved in the UK or Turkey. They provide no reliable basis for claims about current availability in either country, and the GetHair facts sheet does not say that a partner clinic offers the procedure.

How is it different from a follicle transplant?

The NHS describes a hair transplant as moving hair to an area that is thin or bald. In follicular unit transplantation, a strip of hair-bearing skin is removed from the back of the head and divided into grafts. In follicular unit extraction, individual grafts are removed from the donor area. Both approaches place those grafts into small cuts in the scalp (NHS).

Those grafts come from the person having surgery. They contain living follicles that are relocated from one part of the scalp to another (NHS). The FDA’s account of the prosthetic-hair-fibre category states that the fibres did not stimulate hair growth (ISHRS).

This difference also limits comparisons. General NHS timelines for transplanted hair falling out and later growing apply to follicular hair transplantation, not to a synthetic filament becoming living hair (NHS). Likewise, a claim about the appearance of an implanted fibre does not show that it grows, heals or behaves like an autologous follicular graft.

The published sources reviewed for this article do not support a personal suitability test, a maintenance schedule or a removal plan. Those are clinical and device-specific matters that need to be answered by the treating clinic using current documentation for the exact product and procedure.

What do current positions and evidence show?

The ISHRS Board of Governors adopted a statement on 11 December 2021 that aligns the society with the US FDA position on prosthetic hair fibres (ISHRS). The statement records a professional-society position. It neither creates US law nor determines another country’s rules.

The US Code of Federal Regulations lists prosthetic hair fibres under banned devices, with a 3 June 1983 citation. It defines the category as devices intended for implantation into the scalp to simulate natural hair or conceal baldness, while excluding natural hair transplants (21 CFR 895.101). The FDA’s published rationale cited substantial deception and the potential for serious infections, illness and implantation injuries (ISHRS).

The federal regulation names prosthetic hair fibres as a category, not the Biofibre brand (21 CFR 895.101). It does not establish a product’s present regulatory status in the UK or Turkey.

The Biofibre-specific evidence in the brief is a case report published online in November 2025. It describes a 45-year-old man who had synthetic fibres implanted in three sessions in 2021. One year after the final session, he developed itching and inflammatory spots in the implanted crown area (2025 case report).

A scalp biopsy in that case showed inflammation around exogenous filamentous material, with abscesses, multinucleated giant cells and fibrosis. The authors diagnosed a foreign-body granulomatous reaction. They reported partial improvement after clinician-managed treatment, while low-grade inflammation persisted (2025 case report).

A case report can show that this event occurred in one documented patient. It cannot calculate incidence, identify how likely the same outcome is for another person or prove that every synthetic-fibre product and generation has the same risk. The paper itself calls for caution and notes the lack of comprehensive long-term safety data (2025 case report).

Risks and what can go wrong

The FDA’s category-level rationale names serious infection, illness and injury from implantation. Its ban reflects the agency’s US assessment of prosthetic hair fibres and misleading safety or effectiveness claims at the time of the decision (ISHRS). It does not provide a modern Biofibre complication rate.

The 2025 Biofibre report concerns one patient. It documents delayed scalp inflammation, pustules, damaged fibres and a biopsy-confirmed foreign-body reaction in one man. Mild inflammatory activity remained after two months of treatment (2025 case report). The report documents a possible adverse event but provides no probability estimate.

Conventional follicular hair transplantation has its own risks. The NHS lists bleeding, infection, an allergic reaction to anaesthetic, visible scarring and the possibility that a transplant does not take (NHS). Those points describe follicular transplant surgery. They should not be used as a complete risk list for implanted manufactured fibres.

Treatment abroad adds practical questions about insurance and access to help. NHS guidance advises UK nationals to arrange comprehensive travel insurance and directs readers to a treatment-abroad risk checklist before deciding (NHS: Going abroad for treatment). A clinic should explain who provides urgent clinical review, where follow-up takes place and what happens if a complication appears after you return home.

Marketing language can create another risk if it blurs the difference between a manufactured filament and a living follicle (21 CFR 895.101; NHS). Ask for the exact device name, written regulatory evidence for the country where treatment would occur, and evidence that relates to that product rather than the whole category. Do not treat a US category ban, an international society position or one case report as proof of current UK or Turkish status.

Questions to ask the clinic

The clinic should answer these questions with documents that can be checked. A professional-society statement, a US regulatory category and a single case report each answer different questions; none supplies a personal recommendation (ISHRS; 21 CFR 895.101; 2025 case report).

Talk it through

If you are comparing hair-restoration procedures, GetHair can arrange a free consultation and put you in touch with a partner clinic. The clinic assesses, plans and performs treatment; GetHair arranges the introduction and support.

Sources